Other

Heterocyclic compounds with nitrogen hetero-atom(s) only: > Other: > Other: > Aromatic or modified aromatic: > Other: > Drugs: > Other

Duty Rate (from China)

6.5%
MFN Base Rate6.5%

Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter

Total Effective Rate6.5%

Products classified under HTS 2933.99.75.00

Imatinib Mesylate

Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.

Erlotinib Hydrochloride

Erlotinib hydrochloride is an epidermal growth factor receptor (EGFR) inhibitor used in non-small cell lung cancer treatment. As a quinazoline derivative (aromatic heterocycle with nitrogen), it qualifies under HTS 2933.99.75.00 for aromatic heterocyclic drugs.

Nilotinib Hydrochloride

Nilotinib hydrochloride treats imatinib-resistant chronic myelogenous leukemia. As a pyrimidine derivative with aromatic nitrogen heterocycles, it falls under the 'drugs: other' provision of HTS 2933.99.75.00.

Gefitinib

Gefitinib is an EGFR tyrosine kinase inhibitor for lung cancer treatment. This 4-anilinoquinazoline (aromatic N-heterocycle) is classified as a bulk pharmaceutical drug under HTS 2933.99.75.00.

Osimertinib Mesylate

Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.

Brigatinib

Brigatinib is an ALK inhibitor for lung cancer treatment. This macrocyclic aromatic nitrogen-heterocycle drug substance imports under HTS 2933.99.75.00.

Alectinib Hydrochloride

Alectinib hydrochloride targets ALK fusion proteins in lung cancer. As an isoquinoline derivative (aromatic N-heterocycle), classified under HTS 2933.99.75.00 for drugs.

Dasatinib

Dasatinib is a multi-kinase inhibitor used for Philadelphia chromosome-positive leukemias. This thiazole-containing aromatic heterocyclic compound is imported as a bulk drug substance under HTS 2933.99.75.00.

Lapatinib Ditosylate

Lapatinib ditosylate is a dual tyrosine kinase inhibitor for HER2-positive breast cancer. The core quinazoline structure (aromatic heterocyclic with nitrogen) places it under HTS 2933.99.75.00 as a drug.

Afatinib Dimaleate

Afatinib dimaleate is an irreversible EGFR inhibitor for non-small cell lung cancer. As a quinazoline-based aromatic nitrogen heterocycle drug, it falls under HTS 2933.99.75.00.